Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound


Roubaud G., ÖZGÜROĞLU M., Penel N., Matsubara N., Mehra N., Kolinsky M. P. , ...Daha Fazla

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31 identifier